LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Lantheus Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$99.92+0.22 (+0.22%)
Close on Oct 19, 2026
- Market cap
- $6.75B
- P/E (TTM)
- 24.2
- Dividend yield
- –
Lantheus Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $1.51B | $1.51B | $1.51B | $1.51B | $1.50B | $1.52B | $1.52B | $1.47B | $1.42B | $1.34B | $1.26B | $1.18B | 97.2% | +0.6% |
| PYLARIFY | $962.11M | $972.39M | $989.12M | $1.01B | $1.03B | $1.06B | $1.06B | $1.02B | $977.44M | $914.70M | $851.30M | $782.06M | 61.8% | -7.0% |
| DEFINITY | $340.00M | $335.66M | $330.25M | $331.10M | $326.28M | $320.44M | $317.79M | $304.71M | $295.08M | $287.51M | $279.77M | $270.31M | 21.8% | +4.2% |
| Neuraceq | $126.50M | $86.89M | $51.45M | $20.44M | $0 | – | $0 | – | – | – | – | – | 8.1% | – |
| Strategic partnerships and other revenue | $73.30M | $64.98M | $59.38M | $43.74M | $45.28M | $42.42M | $38.18M | $53.28M | $45.35M | $49.41M | $51.88M | $36.32M | 4.7% | +61.9% |
| License and royalty revenues | $43.42M | $35.67M | $34.04M | $19.67M | $16.48M | $14.31M | $9.13M | $22.91M | $19.21M | $25.50M | $33.36M | $23.87M | 2.8% | +163.6% |
| Techne Lite | – | – | $86.80M | $90.93M | $90.28M | $93.48M | $95.49M | $91.90M | $94.69M | $88.10M | $87.37M | $90.58M | – | – |
| Total precision diagnostics | – | – | $493.11M | $467.33M | $441.37M | $437.66M | $437.51M | $420.62M | $413.24M | $398.71M | $390.12M | $383.91M | – | – |
| Total radiopharmaceutical oncology | – | – | $989.12M | $1.01B | $1.03B | $1.06B | $1.06B | $1.02B | $979.42M | $917.50M | $854.43M | $785.36M | – | – |
| Other precision diagnostics | – | – | $24.62M | $24.86M | $24.81M | $23.74M | $24.23M | $24.02M | $23.48M | $23.10M | $22.98M | $23.02M | – | – |
| Other radiopharmaceutical oncology | – | – | $0 | $0 | $0 | $0 | $384.00K | $1.13M | $1.98M | $2.80M | $3.13M | $3.30M | – | – |
By region
From the segment and revenue-disaggregation notes of Lantheus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.